The Global HPV Testing and Pap Test Market Size was valued at USD 3.25 Billion in 2022 and the Worldwide HPV Testing and Pap Test Market Size is expected to reach USD 11.63 Billion by 2032, according to a research report published by Spherical Insights & Consulting. Companies Covered: Abbott Laboratories, Qiagen N.V., Becton, Dickinson & Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific, Inc., BioMerieux SA and Other key vendors.
New York, United States, Nov. 21, 2023 (GLOBE NEWSWIRE) — The Global HPV Testing and Pap Test Market Size is to grow from USD 3.25 Billion in 2022 to USD 11.63 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 13.6% during the forecast period.
Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/2521
HPV testing and Pap test are vital cervical cancer screening methods for women. The Pap test involves collecting cervical cells to detect abnormalities and pre-cancerous changes. It helps identify early signs of cervical cancer for timely intervention. HPV testing analyzes cervical samples to detect high-risk HPV strains, which can lead to cervical cancer. Both tests are often performed together or as follow-ups to ensure comprehensive screening. Regular screenings are crucial for early detection and effective management of cervical cancer, promoting women’s reproductive health.
Browse key industry insights spread across 200 pages with 150 market data tables and figures & charts from the report on “Global HPV Testing and Pap Test Market Size, Share, and COVID-19 Impact Analysis, By Test Type (HPV Testing and Pap Test), By Application (Cervical Cancer Screening and Vaginal Cancer Screening), By Product (Instruments, Consumables, and Services), By Technology (PCR, Immunodiagnostics, and Others), By End-Use (Hospitals & Clinics, Laboratories, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032.”
Buy Now Full Report: https://www.sphericalinsights.com/checkout/2521
The PCR segment is expected to grow at the fastest CAGR of around 12.5% during the forecast period.
Based on the technology, the global HPV testing and Pap test market is segmented into PCR, immunodiagnostics, and others. The PCR (Polymerase Chain Reaction) segment is projected to experience the fastest growth during the forecast period in the HPV testing and Pap test market due to its high sensitivity and specificity in detecting HPV infections. PCR-based tests can accurately identify and differentiate various HPV strains, including high-risk types associated with cervical cancer. As technology continues to advance, PCR methods are becoming more accessible, cost-effective, and user-friendly, leading to increased adoption. Moreover, healthcare providers and patients alike are recognizing the benefits of PCR-based tests in early detection, driving higher demand and contributing to the segment’s rapid growth in the market.
The consumables segment held the largest market share with more than 57.4% in 2022.
Based on the product, the global HPV testing and Pap test market is segmented into instruments, consumables, and services. The consumables segment has emerged as the dominant force in the HPV testing and Pap test market for several significant reasons. Consumables, such as testing kits, collection devices, and reagents, are essential components required for conducting HPV testing and Pap smears. As these tests are performed regularly for cervical cancer screening, the demand for consumables remains consistently high. Moreover, consumables are often associated with repeat purchases, providing a continuous revenue stream for manufacturers. Additionally, the consumables segment’s dominance is further driven by the growing adoption of cervical cancer screening programs worldwide, which necessitates a steady supply of consumables, thereby contributing to its leading position in the market.
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/2521
Asia-Pacific is predicted to grow at a higher CAGR of around 13.8% over the projected period.
Based on region, Asia-Pacific is anticipated to experience exponential growth during the forecast period for several compelling reasons. The region has a large population, including a substantial number of women in the target age group for cervical cancer screenings, creating a significant market opportunity. Increasing awareness about cervical cancer and the importance of early detection is driving higher demand for HPV testing and Pap smears. The improving healthcare infrastructure and rising disposable incomes are facilitating better access to healthcare services, including screening tests. Moreover, government initiatives and collaborations with international organizations are promoting preventive healthcare measures, fueling market expansion. These factors collectively contribute to the projected exponential growth of the HPV testing and Pap test market in Asia-Pacific.
The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. the major players in the global HPV testing and Pap test market include Abbott Laboratories, Qiagen N.V., Becton, Dickinson & Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific, Inc., BioMerieux SA and others.
Get Discount At @ https://www.sphericalinsights.com/request-discount/2521
- In June 2022, Roche has announced the availability of a self-sampling method for human papillomavirus (HPV) in countries that recognize the CE certification. This novel approach allows a patient to take a sample for HPV screening in solitude. The clinically verified vaginal sample is tested on a Roche molecular equipment using the Roche Cobas HPV test.
- In May 2021, Becton, Dickinson, and Company announced the CE marking of the industry’s first self-collection claim for HPV screening in accordance with IVD Directive 98/79/EC. The new claim allows laboratories and facilities to use the BD Onclarity HPV Assay on either the BD Viper LT or the BD COR System to process self-collected samples using a BD diluent tube.
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global HPV testing and Pap test market based on the below-mentioned segments:
HPV Testing and Pap Test Market, By Test Type
- HPV Testing
- Pap Test
HPV Testing and Pap Test Market, By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
HPV Testing and Pap Test Market, By Product
HPV Testing and Pap Test Market, By Technology
HPV Testing and Pap Test Market, By End-Use
- Hospitals & Clinics
HPV Testing and Pap Test Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Browse Related Reports
Europe Digital Health Market Size, Share, and COVID-19 Impact Analysis, By Component (Hardware, Software, and Services), By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems, Others), and By Country (Germany, UK, France, Italy, Spain, Russia, Rest of Europe), and Europe Digital Health Market Insights Forecasts to 2032
Global Biotechnology Instruments Market Size, Share, and COVID-19 Impact Analysis, By Product (Analytical Instruments, Cell Culture Instruments, Cell Separation Instruments, Immunoassay Instruments, Clinical Chemistry Analyzers, Others), By End-Users (Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
Global Collagen Dressing Market Size, Share, and COVID-19 Impact Analysis, By Form (Gel, Pads, Powder, Sheet, and Others), By Source (Bovine, Equine, and Others), By Type (Antimicrobial Collagen Dressing, Hydrogel Collagen Dressing, and Alginate Collagen Dressing), By End-use (Hospitals, Specialty Clinics, Home Healthcare, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
Global Melanoma Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Product (Chemotherapy, Immunotherapy, Targeted Therapy, and Radiation Therapy), By Drug Type (Branded Drugs and Generic Drugs), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company’s mission is to work with businesses to achieve business objectives and maintain strategic improvements.
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Contact Us: https://www.sphericalinsights.com/contact-us
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.